Stereotaxis, Inc., developer of an advanced cardiology instrument control system, today announced it has completed the first 50 clinical procedures using the company’s new NiobeES™ system to treat a variety of complex cardiac arrhythmias.
The majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia. The company reports that positive initial results of the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes. The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on Jan. 12-14, 2012.
Stereotaxis’ Epoch™ platform encompasses the Niobe ES system, and is the company’s new generation comprehensive solution for the electrophysiology (EP) laboratory. Epoch uses a remote, networked and modular robotic, magnetic system to improve efficiency and surgical precision.
“My vision was to click on the map and for the catheter to quickly and precisely move to that spot. Today with the Epoch platform, this is a reality. I believe the Epoch platform is one of the most important innovations for the EP practice to date. With the Epoch technology all physicians can successfully and consistently perform high quality AF procedures with the assurance of superior patient care,” Professor Carlo Pappone of Villa Maria Cecilia Hospital, Cotignola Italy, stated in the press release.
Based on positive response, the company anticipates releasing a dozen product upgrades within in the next few months.
“The initial feedback and interest in our new Epoch platform has been very favorable,” said Michael P. Kaminski, president and CEO of Stereotaxis. “We look forward to continuing to build on the momentum of this milestone and have commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months.”
Let us hear your thoughts below: